PurpleLab and the business of making healthcare make sense

A medical claim has an unromantic purpose: getting someone paid. Yet inside its codes sits a partial account of a person’s life. A consultation. A procedure. A prescription collected, or collected again. Put those fragments together and a pattern appears. Put them together badly and the pattern may be an artefact of your bookkeeping. PurpleLab has built its business in the space between those two possibilities.

The company reports coverage of more than 330 million US patient lives and over 14 billion medical and pharmacy claims annually. Those are data-footprint figures, not a census of paying customers or a promise that every person has a complete record. The more interesting question is what happens after the records arrive. Someone must decide which codes belong together, which encounters count and whether the same question will mean the same thing next month.

01 / The translation comes first

Consider a hypothetical drug team trying to understand a treatment market. Counting a diagnosis code sounds straightforward. But which diagnoses qualify? Which procedures support the definition? Which patients should be excluded? Change those rules between reports and the apparent movement in the market may be movement in the measuring instrument. An attractive chart can be remarkably well dressed for someone who has misunderstood the question.

PurpleLab’s answer is harmonization. Its CLEAR methodology organizes medical and pharmacy claims into a de-identified dataset, with clinical and demographic context. HealthNexus supplies the working interface: a no-code platform for exploring populations, designing cohorts, examining providers and following treatment patterns. The company also maintains relationships between providers and organizations, helping users understand where care happens rather than treating every practitioner as an isolated dot.

“the biggest challenge lies in the ability to readily interpret the data”

Mark Brosso · 2022 funding announcement

That is the commercial proposition beneath the software. A life sciences analyst can investigate a market; a research team can examine a population; an agency can develop an audience. The platform reduces the need to commission a fresh technical exercise for every variation of a question. It still requires somebody who knows what a clinically sensible question looks like.

02 / A founder who knew the paperwork

Founder and CEO Mark Brosso came to the problem with previous healthcare-data businesses behind him. He founded Health Market Science in 1999 and later created Aileron Solutions, which IMS Health bought in 2014. In a 2023 Edison Partners interview, he described an early business idea built around counting case volumes for surgeons and cardiologists. The recurring interest was practical: turning records into information someone could use.

The financing followed that logic. Edison announced $3 million in growth financing in August 2019, when PurpleLab offered subscription access to provider-profiling queries and reports. Its $40 million Series B, led by Primus Capital with existing investor Edison, closed in July 2022. PurpleLab said the money would support new data assets, product development and people. This is a business in which improving the ingredients can matter as much as improving the menu.

03 / The bill leaves things out

Claims tell you what was recorded for payment. Clinical notes can contain another layer of explanation. In September 2025, PurpleLab acquired KAID Health, whose Whole Chart Analysis technology uses artificial intelligence and natural-language processing to examine structured electronic medical-record data and narrative notes. The combination extends PurpleLab toward coding, chart review, care management and more precise cohort identification.

The distinction matters. A larger pile of claims cannot, by itself, supply every observation a clinician wrote down elsewhere. KAID adds a different kind of information and a means of reading it. PurpleLab described the acquisition as a move toward becoming an AI-first healthcare intelligence company. The concrete change is easier to assess than the slogan: structured records and unstructured narrative can now inform a broader set of workflows.

The company has also added financial detail. Its September 2025 data announcement described 17 billion remittance records dating back to 2014, including allowed amounts, patient responsibility and denial reasons. Separate partnerships with Payerset and Lime Tree Health brought price-transparency data into the offering. What was billed, what was allowed and what a patient owes are different questions. Treating them as interchangeable is an expensive shortcut.

04 / Advertising wants an ending

Healthcare advertising is another customer for this infrastructure. PurpleLab offers healthcare-professional audiences, modeled consumer audiences and campaign measurement. Its January 2026 measurement launch combined exposure ingestion, outcomes analysis and reporting through HealthNexus, APIs and custom services. Agencies and pharmaceutical marketers can examine prescribing shifts and treatment-related signals alongside campaign activity, rather than stopping at the impression count.

Social media creates a particularly awkward boundary. PurpleLab’s March 2026 announcement said platform exposure data could not simply leave those environments, while healthcare data could not simply be uploaded into them. Its partnership with Decentriq uses confidential computing and data clean rooms to analyze the datasets together. In September, a Chalice AI partnership added brand-specific predictive models intended to inform audience selection and media decisions.

Privacy is part of the product architecture. PurpleLab says its CLEAR Claims data meets HIPAA de-identification standards through expert determination. Its privacy policy describes consumer audiences as tokenized, modeled groups indicating potential interests, with distribution through partners. That distinction deserves attention: an advertising audience is a constructed product, not an invitation to inspect an identifiable person’s medical file.

05 / Borrow the discipline

PurpleLab occupies overlapping markets: healthcare data, enterprise analytics and pharmaceutical advertising intelligence. Buyers may also consider Komodo Health or IQVIA for data and analysis, and Veeva Crossix for advertising measurement. PurpleLab’s pitch combines a harmonized foundation, a self-service interface and activation and measurement workflows. The sensible comparison starts with the task, the required population and the permissions, rather than the biggest number on a sales slide.

The habit any reader can copy is simple: define the outcome before building the report. Keep population rules stable. Check continuity as well as coverage. Ask whether the information actually contains the event you want to study. No-code access makes investigation easier; it does not turn an association into a causal finding. PurpleLab’s interesting bet is that healthcare decisions improve when the difficult work of interpretation becomes easier to repeat.